Radical Honesty Is Part Of The Secret To Apellis's Success

On the heels of Apellis's wildly successful launch for the geographic atrophy drug Syfovre, the company's co-founder and CEO spoke with In Vivo about what it takes to go from a start-up to a commercial-stage company and about the importance of honesty in leadership.

Apellis
Syfovre Earned Apellis Pharmaceuticals $18.4m Within Roughly A Month Of Launch • Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc.'s CEO Cedric Francois, one of In Vivo’s 2023 Rising Leaders, has come by his penchant for innovation honestly. As a pediatric and transplant surgeon, Francois was on the University of Louisville, Kentucky, research team that in 1999 performed the first successful vascularized composite allograft hand transplant. During his time at Louisville, a mentor shared a sentiment on visionary leadership that has supported Francois through his entrepreneurial endeavors.

Self-assuredness helped Francois in co-founding Potentia Pharmaceuticals, the first company to test complement-inhibiting therapies in age-related macular degeneration, and then...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Rising Leaders

Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future clone3

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

In Vivo’s 2026 Rising Leaders

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

More from Leadership

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

In Vivo’s 2026 Rising Leaders

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.